TALEN gene editing takes aim on HIV

Area of Science:

• Molecular Biology
• Gene Therapy
• Virology

Background:

• Transcription activator-like effector nucleases (TALENs) are engineered nucleases for targeted DNA cleavage.
• HIV infection remains a significant global health challenge requiring innovative therapeutic strategies.

Purpose of the Study:

• To review the potential, progress, and challenges of using TALENs for therapeutic HIV infection treatment.
• To compare TALENs with CRISPR/Cas-9 in terms of efficacy and safety for HIV gene therapy.

Main Methods:

• TALENs target specific DNA sequences in host genes (e.g., CCR5, CXCR4, LEDGF/p75) or viral DNA (long terminal repeats).
• Cellular DNA repair mechanisms introduce insertions or deletions (indels) at the cleavage site.

Main Results:

• TALENs demonstrate reduced off-target editing and better tolerance to HIV escape mutations compared to CRISPR/Cas-9.
• Ongoing technological advancements are improving TALENs' cleavage efficiency and specificity.

Conclusions:

• TALENs present a potential paradigm shift from lifelong antiretroviral therapy to HIV eradication.
• Further therapeutic testing in animal models is necessary to validate TALENs as a safe and effective HIV treatment.